Hormone Replacement Therapy After Risk-Reducing Surgery in Women at Increased Risk for Breast Cancer: The Patient Perspective
https://www.facingourrisk.org/research-clinical-trials/study/337/hrt-after-risk-reducing-surgery-in-women-at-increased-risk-for-breast-cancer-the-patient-perspective
Surveys, Registries, Interviews
Survey for women with a BRCA1, BRCA2, PALB2, RAD51C, RAD51D genetic mutation who have undergone risk-reducing bilateral salpingo-oophorectomy (removed both tubes and ovaries) to lower cancer risk
Study Contact Information:
Emily Stevens, [email protected], 289-689-3425
Erika Renkes, [email protected], 815-441-5003
Jill Stopfer, [email protected]
About the Study
In this study, we aim to better understand patient perceptions about hormone replacement therapy (HRT) and identify factors informing decision making about HRT for use in women who have a BRCA1, BRCA2, PALB2, RAD51C or RAD51D genetic mutation that increases breast and ovarian cancer risk.
Individuals who have undergone risk-reducing surgery for ovarian cancer will be asked to complete a survey about their thoughts, experiences and understanding of the risks and benefits related to hormone replacement therapy.
What the Study Involves
Participants will be asked to complete one online survey estimated to take about 15-20 minutes. There is no follow-up after completing the survey. Participation is voluntary and participants can choose to opt out of the study at any point without consequence. Participants also have the option to skip questions without justification. Survey responses will be kept anonymous and identifying information will not be shared. Every reasonable effort will be made to keep data secure. Participants will not receive monetary compensation. However, it is hoped this research will lead to a better understanding of factors influencing women’s decisions about HRT and all participation is appreciated.
Lead Researchers
Emily Stevens, Genetic Counseling Student
Sarah Lawrence College, Bronxville, NY
This Study is Open To:
- 35-50 years old
- no previous history of a breast cancer diagnosis
- have undergone preventative surgical removal of both ovaries and fallopian tubes (ie. risk-reducing salpingo-oophorectomy)
- confirmed BRCA1, BRCA2, PALB2, RAD51C or RAD51D genetic mutation
This Study is Not Open To:
- A personal history of a breast cancer diagnosis
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.